Degli Esposti M, Rotilio G, Lenaz G
Biochim Biophys Acta. 1984 Oct 26;767(1):10-20. doi: 10.1016/0005-2728(84)90074-4.
We have investigated in detail the effects of dibromothymoquinone (2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone, DBMIB) on the ubiquinol-cytochrome c reductase (cytochrome bc1 complex) from bovine heart mitochondria. The inhibitory action of DBMIB on the steady-state activity of the bc1 complex is related to the specific binding of the quinone to the purified enzymatic complex. At concentrations higher than 10 mol per mol of the enzyme, DBMIB is able to stimulate an antimycin-insensitive reduction of cytochrome c catalyzed by the bc1 complex. In accordance with kinetic data showing a competition by endogenous ubiquinone in the inhibitory action, DBMIB can be considered as a product-like inhibitor of the ubiquinol-cytochrome c reductase activity. The site of specific binding of dibromothymoquinone in the bc1 complex enables it to interact with the iron-sulphur center of the enzyme, as indicated by changes induced in the EPR spectrum of the center. However, the inhibitor also directly interacts with cytochrome b, promoting a fast chemical oxidation of the reduced heme center. In spite of these effects, DBMIB has been found not to exert significant effects on the first turnover of the fully oxidized bc1 complex, as monitored by the rapid reduction of both cytochromes b and c1 by ubiquinol-1. In the presence of antimycin, only a stimulation of cytochrome c1 reduction, in parallel to an enhanced cytochrome b reoxidation, is observed. Moreover, DBMIB does not affect the oxidant-induced extra cytochrome b reduction in the presence of antimycin. On the basis of the evidences suggesting a competition with the endogenous ubiquinone in the redox cycle of the bc1 complex, a model is proposed for the mechanism of DBMIB inhibition. Such model can also explain at the molecular level the redox bypass induced by dibromothymoquinone in the whole respiratory chain (Degli Esposti, M., Rugolo, M. and Lenaz, G. (1983) FEBS Lett. 156, 15-19).
我们详细研究了二溴百里醌(2,5 - 二溴 - 3 - 甲基 - 6 - 异丙基 - 对苯醌,DBMIB)对牛心线粒体泛醇 - 细胞色素c还原酶(细胞色素bc1复合体)的影响。DBMIB对bc1复合体稳态活性的抑制作用与醌与纯化酶复合体的特异性结合有关。当浓度高于每摩尔酶10摩尔时,DBMIB能够刺激bc1复合体催化的细胞色素c的抗霉素不敏感还原。根据动力学数据显示内源性泛醌在抑制作用中的竞争,DBMIB可被视为泛醇 - 细胞色素c还原酶活性的类产物抑制剂。二溴百里醌在bc1复合体中的特异性结合位点使其能够与酶的铁硫中心相互作用,如该中心的电子顺磁共振谱所诱导的变化所示。然而,该抑制剂也直接与细胞色素b相互作用,促进还原血红素中心的快速化学氧化。尽管有这些影响,但已发现DBMIB对完全氧化的bc1复合体的首次周转没有显著影响,这通过泛醇 - 1对细胞色素b和c1的快速还原进行监测。在存在抗霉素的情况下,仅观察到细胞色素c1还原的刺激,同时伴随着细胞色素b再氧化的增强。此外,在存在抗霉素的情况下,DBMIB不影响氧化剂诱导的额外细胞色素b还原。基于表明在bc1复合体的氧化还原循环中与内源性泛醌竞争的证据,提出了DBMIB抑制机制的模型。该模型还可以在分子水平上解释二溴百里醌在整个呼吸链中诱导的氧化还原旁路(Degli Esposti, M., Rugolo, M.和Lenaz, G. (1983) FEBS Lett. 156, 15 - 19)。